Metabolic changes in patients with prostate cancer with androgen deprivation therapy

Prostate cancer is the most common type of cancer among men. Androgen deprivation therapy (ADT) is the most effective treatment for this disease. The cornerstone of prostate cancer treatment is the inhibition of testosterone production, which interrupts testosterone-induced growth of the prostate tumour. A sharp decrease in testosterone, however, has several undesirable effects on the metabolic profile and bone metabolism and can also lead to fatigue, loss of libido, gynecomastia and anaemia, provoke vasomotor hyperaemia and generally affect the quality of life. To increase the good (long-term) survival of patients with prostate cancer, studying the side effects associated with treatment is important, and therefore, in every clinical situation, the benefits of ADT must be compared with the side effects associated with the treatment. This article focuses on the described metabolic complications of ADT, including obesity, diabetes, lipid changes, metabolic syndrome and cardiovascular diseases. It also contains practical recommendations for managing the side effects and complications based on the available guidelines issued by the medical professional community.

1. Ryan CJ, Small EJ. Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate. J Clin Oncol. 2005;23(32):8225–8231. doi: https://doi.org/10.1200/JCO.2005.03.5311

2. Каприн А.Д., Троянов А.В., Иванов С.А., Карякин О.Б. Комплексное гормонохимиолучевое лечение больных неметастатическим раком предстательной железы группы высокого и очень высокого риска прогрессирования // Онкоурология. — 2017. — T. 13. — №1. — С. 101–111. [Kaprin AD, Troyanov AV, Ivanov SA, Karyakin OВ. Combined chemohormonalradiation treatment of highand very-high-risk non-metastatic prostate cancer. Onkouro. 2017;13(1):101–111. (In Russ.)] doi: https://doi.org/10.17650/1726-9776-2017-13-1-101-111

3. Алексеев Б.Я. Новые возможности комбинированной антиандрогенной терапии больных метастатическим гормоночувствительным раком предстательной железы // Онкоурология. — 2019. — Т. 15. — №3. — С. 89–101. [Alekseev BY. New possibilities of combined antiandrogen therapy in patients with metastatic hormone-sensitive prostate cancer. Onkouro. 2019;15(3):89–101. (In Russ.)] doi: https://doi.org/10.17650/1726-9776-2019-15-3-89-101

4. Шестакова М.В., Чазова И.Е., Шестакова Е.А. Российское многоцентровое скрининговое исследование по выявлению недиагностированного сахарного диабета 2 типа у пациентов с сердечно-сосудистой патологией // Сахарный диабет. — 2016. — Т. 19. — №1. — С. 24–29. [Shestakova MV, Chazova IE, Shestakova EA. Russian multicentre type 2 diabetes screening program in patients with cardiovascular disease. Diabetes mellitus. 2016;19(1):24–29 (In Russ.)] doi: https://doi.org/10.14341/DM7765

5. Shahinian VB, Kuo Yf, Freeman JL, et al. Increasing use of gonadotropin releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103(8):1615–1624. doi: https://doi.org/10.1002/cncr.20955.

6. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014;65(1):124–137. doi: https://doi.org/10.1016/j.eururo.2013.09.046

7. Bolla M, Collette L, Blank L, et al. Long term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet. 2002;360(9327):103–106. doi: https://doi.org/10.1016/s0140-6736(02)09408-4

8. Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006;7(6):472–479. doi: https://doi.org/10.1016/S1470-2045(06)70700-8

9. Huggins C, Hodges CV. Studies on prostate cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43(2):209–233. doi: https://doi.org/10.1001/archsurg.1941.01210140043004

10. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65(2):467–479. doi: https://doi.org/10.1016/j.eururo.2013.11.002

11. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2009;181(5):1998–2006. doi: https://doi.org/10.1016/j.juro.2009.01.047

12. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415–1428. doi: https://doi.org/10.1016/S0140-6736(05)66378-7

13. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595–1607. doi: https://doi.org/10.2337/diab.37.12.1595

14. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American diabetes association and the european association for the study of diabetes. Diabetologia. 2005;48(9):2289–2304. doi: https://doi.org/10.2337/diacare.28.9.2289

15. Executive summary of the third report of the national cholesterol education program (ncep) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285(19):2486–2497. doi: https://doi.org/10.1001/jama.285.19.2486

16. Gallagher EJ, Leroith D, Karnieli E. The metabolic syndrome — from insulin resistance to obesity and diabetes. Med Clin North Am. 2011;95(5):855–873. doi: https://doi.org/10.1016/j.mcna.2011.06.001

17. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2013;189(1 Suppl):S34–42. doi: https://doi.org/10.1016/j.juro.2012.11.017

18. Nobes JP, Langley SE, Laing RW. Metabolic syndrome and prostate cancer: a review. Clin Oncol (R Coll Radiol). 2009;21(3):183–191. doi: https://doi.org/10.1016/j.clon.2008.11.013

19. Leahy Y. Risk of metabolic syndrome, cardiovascular disease, and diabetes in androgen deprivation therapy. Clin J Oncol Nurs. 2008;12(5):771–776. doi: https://doi.org/10.1188/08.CJON.771-776

20. Saigal CS, Gore JL, Krupski TL, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110(7):1493–1500. doi: https://doi.org/10.1002/cncr.22933

21. Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol. 2009;27(1):92–99. doi: https://doi.org/10.1200/JCO.2007.12.3752

22. Van Poppel H, Tombal B. Cardiovascular risk during hormonal treatment in patients with prostate cancer. Cancer Manag Res. 2011;3:49–55. doi: https://doi.org/10.2147/CMR.S16893

23. Roayaei M, Ghasemi S. Effect of androgen deprivation therapy on cardiovascular risk factors in prostate cancer. J Res Med Sci. 2013;18(7):580–582.

24. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002;168(1):9–12. doi: https://doi.org/10.1016/s0022-5347(05)64820-3

25. Roach M. 3rd. Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate-risk, high-risk, localized, and locally advanced prostate cancer. Cancer. 2014;120(11):1620–1629. doi: https://doi.org/10.1002/cncr.28594

26. Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24(24):3979–3983. doi: https://doi.org/10.1200/JCO.2006.05.9741

27. Munoz GJ, Samper OP, Rios KY, et al. Cross-section observational study about prevalence of metabolic syndrome and osteoporosis in prostate cancer treated with androgen-deprivation therapy and their impact on quality of life (SIMBOSPROST): Gicor Group. Intl J Rad Onc Bio Phys. 2013;87(2):356. doi: https://doi.org/10.1016/j.ijrobp.2013.06.934

28. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome: a new worldwide definition. Lancet. 2005;366(9491):1059–1062. doi: https://doi.org/10.1016/S0140-6736(05)67402-8

29. Tsai HT, Keating NL, van Den Eeden SK, et al. Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer. J Urol. 2015;193(6):1956–1962. doi: https://doi.org/10.1016/j.juro.2014.12.027

30. Basaria S, Muller DC, Carducci MA, et al. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer. 2006;106(3):581–588. doi: https://doi.org/10.1002/cncr.21642

31. Bastian PJ, Boorjian SA, Bossi A, et al. High-risk prostate cancer: from definition to contemporary management. Eur Urol. 2012;61(6):1096–1106. doi: https://doi.org/10.1016/j.eururo.2012.02.031

32. Yu IC, Lin HY, Sparks JD, et al. Androgen receptor roles in insulin resistance and obesity in males: the linkage of androgen-deprivation therapy to metabolic syndrome. Diabetes. 2014;63(10):3180–3188. doi: https://doi.org/10.2337/db13-1505

33. Vermeulen A, Goemaere S, Kaufman JM. Testosterone, body composition and aging. J Endocrinol Invest. 1999;22(5 Suppl):110–116. doi: https://doi.org/10.3109/13685539909003178

34. Laaksonen DE, Niskanen L, Punnonen K, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004;27(5):1036–1041. doi: https://doi.org/10.2337/diacare.27.5.1036

35. Smith MR, Finkelstein JS, McGovern FJ, et al. Change in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87(2):599–603. doi: https://doi.org/10.1210/jcem.87.2.8299

36. Smith MR, Lee H, McGovern F, et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: Differences from the classic metabolic syndrome. Cancer. 2008;112(10):2188–2194. doi: https://doi.org/10.1002/cncr.23440

37. Trujillo ME, Scherer PE. Adiponectin journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med. 2005;257(2):167–175. doi: https://doi.org/10.1111/j.1365-2796.2004.01426.x

38. Dockery F, Bulpitt CJ, Agarwal S, et al. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinemia. Clin Sci (London). 2003;104(2):195–201. doi: https://doi.org/10.1042/cs20020209

39. Hamilton EJ, Gianatti E, Strauss BJ, et al. Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol. 2011;74(3):377–383. doi: https://doi.org/10.1111/j.1365-2265.2010.03942.x

40. Scailteux LM, Naudet F, Alimi Q. Mortality, cardiovascular risk, and androgen deprivation therapy for prostate cancer: A systematic review with direct and network meta-analyses of randomized controlled trials and observational studies. Medicine (Baltimore). 2016;95(24):e3873. doi: https://doi.org/10.1097/MD.0000000000003873

41. Haffner SM. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol. 2006;97(2A):3A–11A. doi: https://doi.org/10.1016/j.amjcard.2005.11.010

42. Smith MR, Lee H, Fallon MA, Nathan DM. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology. 2008;71(2):318–322. doi: https://doi.org/10.1016/j.urology.2007.08.035

43. Traish AM, Zitzmann M. The complex and multifactorial relationship between testosterone deficiency (TD), obesity and vascular disease. Rev Endocr Metab Disord. 2015;16(3):249–268. doi: https://doi.org/10.1007/s11154-015-9323-2

44. Ullah MI, Washington T, Kazi M, et al. Testosterone deficiency as a risk factor for cardiovascular disease. Horm Metab Res. 2011;43(3):153–164. doi: https://doi.org/10.1055/s-0030-1270521

45. Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448–4456. doi: https://doi.org/10.1200/JCO.2006.06.2497

46. Cutolo M, Sulli A, Capellino S, et al. Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity. Lupus. 2004;13(9):635–638. doi: https://doi.org/10.1191/0961203304lu1094oa

47. Smith RM. Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors. Curr Urol Rep. 2008;9(3):197–202. doi: https://doi.org/10.1007/s11934-008-0035-y

48. Alibhai SM, Duong-Hua M, Sutradhar R, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol. 2009;27(21):3452–3458. doi: https://doi.org/10.1200/JCO.2008.20.0923

49. Keating NL, O’Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010;102(1):39–46. doi: https://doi.org/10.1093/jnci/djp404

50. Keating NL, Liu PH, O’Malley AJ, et al. Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. Eur Urol. 2014;65:816−824. doi: https://doi.org/10.1016/j.eururo.2013.02.023

51. Morote J, Gomez-Caamano A, Alvarez-Ossorio JL, et al. The metabolic syndrome and its components in patients with prostate cancer on androgen deprivation therapy. J Urol. 2015;193(6):1963–1969. doi: https://doi.org/10.1016/j.juro.2014.12.086

52. American Diabetes Association. Standards of medical care in diabetes–2008. Diabetes Care. 2008;31 Suppl 1:S12–54. doi: https://doi.org/10.2337/dc08-S012

53. Finkelstein JS, Lee H, Burnett-Bowie SA, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;12;369(11):1011–1022. doi: https://doi.org/10.1056/nejmoa1206168

54. Allan CA, McLachlan RI. Androgens and obesity. Curr Opin Endocrinol Diabetes Obes. 2010;17(3):224–232. doi: https://doi.org/10.1097/MED.0b013e3283398ee2

55. Brand JS, van der Tweel I, Grobbee DE, et al. Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int J Epidemiol. 2011;40(1):189–207. doi: https://doi.org/10.1093/ije/dyq158

56. Lee H, McGovern K, Finkelstein JS, Smith MR. Changes in bone mineral density and body composition during initial and long-term gonadotropinreleasing hormone agonist treatment for prostate carcinoma. Cancer. 2005;104(8):1633–1637. doi: https://doi.org/10.1002/cncr.21381

57. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006;91(4):1305–1308. doi: https://doi.org/10.1210/jc.2005-2507

58. Hamilton EJ, Gianatti E, Strauss BJ et al. Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol (Oxf). 2011;74(3):377–383. doi: https://doi.org/10.1111/j.1365-2265.2010.03942.x

59. Torimoto K, Samma S, Kagebayashi Y, et al. The effects of androgen deprivation therapy on lipid metabolism and body composition in Japanese patients with prostate cancer. Jpn J Clin Oncol. 2011;41(4):577–581. doi: https://doi.org/10.1093/jjco/hyr005

60. Smith JC, Bennett S, Evans LM, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab. 2001;86(9):4261–4267. doi: https://doi.org/10.1210/jcem.86.9.7851

61. Cheung AS, Hoermann R, Dupuis P, et al. Relationships between insulin resistance and frailty with body composition and testosterone in men undergoing androgen deprivation therapy for prostate cancer. Eur J Endocrinol. 2016;175(3):229–237. doi: https://doi.org/10.1530/EJE-16-0200

62. Salvador C, Planas J, Agreda F, et al. Analysis of the lipid profile and atherogenic risk during androgen deprivation therapy in prostate cancer patients. Urol Int. 2013;90(1):41-44. doi: https://doi.org/10.1159/000342814

63. Stone P, Hardy J, Huddart R, et al. Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer. 2000;36(9):1134–1141. doi: https://doi.org/10.1016/s0959-8049(00)00084-8

64. Zamboni M, Mazzali G, Fantin F, et al. Sarcopenic obesity: a new category of obesity in the elderly. Nutr Metab Cardiovasc Dis. 2008;18(5):388–395. doi: https://doi.org/10.1016/j.numecd.2007.10.002

65. Tian S, Xu Y. Association of sarcopenic obesity with the risk of all-cause mortality: A meta-analysis of prospective cohort studies. Geriatr Gerontol Int. 2016;16(2):155–166. doi: https://doi.org/10.1111/ggi.12579

66. Reis C, Liberman S, Pompeo AC, et al. Body composition alterations, energy expenditure and fat oxidation in elderly males suffering from prostate cancer, pre- and post-orchiectomy. Clinics (Sao Paulo). 2009;64(8):781–784. doi: https://doi.org/10.1590/S1807-59322009000800012

67. Chazenbalk G, Singh P, Irge D, et al. Androgens inhibit adipogenesis during human adipose stem cell commitment to preadipocyte formation. Steroids. 2013;78(9):920–926. doi: https://doi.org/10.1016/j.steroids.2013.05.001

68. Smith JC, Bennett S, Evans LM, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab. 2001;86(9):4261–4267. doi: https://doi.org/10.1210/jcem.86.9.7851

69. Bourke L, Smith D, Steed L, et al. Exercise for men with prostate cancer: A systematic review and meta-analysis. Eur Urol. 2016;69(4):693–703. doi: https://doi.org/10.1016/j.eururo.2015.10.047

70. Culos-Reed SN, Robinson JW, Lau H, et al. Physical activity for men receiving androgen deprivation therapy for prostate cancer: benefits from a 16-week intervention. Support Care Cancer. 2010;18(5):591–599. doi: https://doi.org/10.1007/s00520-009-0694-3

71. Wall BA, Galvão DA, Fatehee N, et al. Exercise improves VO2MAX and body composition in ADT-treated prostate cancer patients. Med Sci Sports Exerc. 2017;49(8):1503–1510. doi: https://doi.org/10.1249/MSS.0000000000001277

72. Shahani S, Braga-Basaria M, Basaria S. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab. 2008;93(6):2042−2049. doi: https://doi.org/10.1210/jc.2007-2595

73. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–1913. doi: https://doi.org/10.1016/S0140-6736(02)11911-8

74. Rezaei MM, Rezaei MM, Ghoreifi A, Kerigh BF. Metabolic syndrome in patients with prostate cancer undergoing intermittent androgen-deprivation therapy. Can Urol Assoc J. 2016;10(9-10):E300–E305. doi: https://doi.org/10.5489/cuaj.3655

75. Csongrádi É, Káplár M, Nagy B Jr, et al. Adipokines as atherothrombotic risk factors in obese subjects: Associations with haemostatic markers and common carotid wall thickness. Nutr Metab Cardiovasc Dis. 2017;27(6):571–580. doi: https://doi.org/10.1016/j.numecd.2017.02.007

76. Wilt TJ, Bloomfield HE, MacDonald R, et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med. 2004;164(13):1427–1436. doi: https://doi.org/10.1001/archinte.164.13.1427

77. Smith MR, Malkowicz SB, Chu F, et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol. 2008;179(1):152–155. doi: https://doi.org/10.1016/j.juro.2007.08.137